Sign In
Buy HRTX
$0.447
-0.0032 (-0.711%)
At Close: Jun 03, 2026
Heron Therapeutics (HRTX) Reports Q2 Loss, Misses Revenue Estimates
09:56am, Friday, 08'th Aug 2025
Heron Therapeutics (HRTX) came out with a quarterly loss of $0.02 per share versus the Zacks Consensus Estimate of a loss of $0.01. This compares to a loss of $0.06 per share a year ago.
Heron (HRTX) Q2 Acute Care Jumps 56%
08:02am, Friday, 08'th Aug 2025
Heron (HRTX) Q2 Acute Care Jumps 56%
Heron Therapeutics Announces Comprehensive Capital Restructuring to Support Growth and Extend Maturity Profile
07:45am, Friday, 08'th Aug 2025
CARY, N.C. , Aug. 8, 2025 Heron Therapeutics, Inc. (Nasdaq: HRTX) ("Heron" or the "Company"), a commercial-stage biotechnology company, today announced the completion of a comprehensive capital restru
Heron Therapeutics Announces Q2 2025 Financial Results and Highlights Commercial Progress
07:45am, Friday, 08'th Aug 2025
Generated Q2 2025 Net Revenue of $37.2 million and year-to-date revenue of $76.1 million; reaffirmed 2025 Net Revenue Guidance of $153 million - $163 million Delivered record year-to-date 2025 Adjuste
Heron Therapeutics Reschedules Second Quarter 2025 Earnings Release and Conference Call to Friday, August 8, 2025
06:00am, Friday, 08'th Aug 2025
CARY, N.C. , Aug. 8, 2025 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX) ("Heron" or the "Company"), a commercial-stage biotechnology company, today announced that it has rescheduled its rele
Heron Therapeutics to Report Second Quarter 2025 Financial Results on Monday, August 11, 2025
09:42pm, Monday, 28'th Jul 2025
CARY, N.C. , July 28, 2025 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX) ("Heron" or the "Company"), a commercial-stage biotechnology company, today announced that the Company will host a co
These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar
09:56am, Monday, 07'th Jul 2025
Finding stocks expected to beat quarterly earnings estimates becomes an easier task with our Zacks Earnings ESP.
These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar
09:56am, Friday, 04'th Jul 2025
Finding stocks expected to beat quarterly earnings estimates becomes an easier task with our Zacks Earnings ESP.
Heron Therapeutics: Q1 Paints A Potentially Rosy Picture For 2025
03:38pm, Wednesday, 07'th May 2025
HRTX's Q1'25 earnings highlight Cinvanti as the top earner, but Zynrelef shows strong growth potential, with 60% growth in net sales vs Q1'24. HRTX reported net income of $2.6M and raised its full-yea
Heron Therapeutics, Inc. (HRTX) Q1 2025 Earnings Call Transcript
11:38am, Tuesday, 06'th May 2025
Heron Therapeutics, Inc. (NASDAQ:HRTX ) Q1 2025 Earnings Conference Call May 6, 2025 8:00 AM ET Company Participants Melissa Jarel - Executive Director, Legal Craig Collard - Chief Executive Officer I
Compared to Estimates, Heron Therapeutics (HRTX) Q1 Earnings: A Look at Key Metrics
10:36am, Tuesday, 06'th May 2025
While the top- and bottom-line numbers for Heron Therapeutics (HRTX) give a sense of how the business performed in the quarter ended March 2025, it could be worth looking at how some of its key metric
Heron Therapeutics (HRTX) Q1 Earnings and Revenues Top Estimates
09:56am, Tuesday, 06'th May 2025
Heron Therapeutics (HRTX) came out with quarterly earnings of $0.01 per share, beating the Zacks Consensus Estimate of a loss of $0.01 per share. This compares to loss of $0.02 per share a year ago.
Heron Therapeutics Announces First Quarter 2025 Financial Results and Highlights Recent Corporate Updates
07:45am, Tuesday, 06'th May 2025
Generated Q1 2025 Net Revenue of $38.9 million Delivered record Q1 2025 Adjusted EBITDA of $6.2 million Reached settlement with Mylan Pharmaceuticals, Inc., regarding the parties' CINVANTI ® and APON
Heron Therapeutics Announces Settlement with Mylan Related to CINVANTI® and APONVIE® Patent Litigations
07:30am, Tuesday, 06'th May 2025
— Company Grants Mylan a License to Market Generic CINVANTI® and APONVIE® Beginning in June 2032 — CARY, N.C. , May 6, 2025 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX) ("Heron" or
Heron Therapeutics (HRTX) Expected to Beat Earnings Estimates: What to Know Ahead of Q1 Release
11:06am, Tuesday, 29'th Apr 2025
Heron Therapeutics (HRTX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
